93 related articles for article (PubMed ID: 26909356)
1. RAS MAPK inhibitors deregulation in leukemia.
Pasmant E; Vidaud D; Ballerini P
Oncoscience; 2015; 2(12):930-1. PubMed ID: 26909356
[No Abstract] [Full Text] [Related]
2. [Relationship between Spred1 and acute myeloid leukemia].
Zhang Y; Li Y; Zhang R
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):1083-7. PubMed ID: 23998617
[TBL] [Abstract][Full Text] [Related]
3.
Zhang R; Zhang Y; Lu X; Xu W; Wang H; Mo W; Pang H; Tang R; Li S; Yan X; Li Y
Front Oncol; 2020; 10():204. PubMed ID: 32175275
[TBL] [Abstract][Full Text] [Related]
4. The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome.
Lu D; Nounou R; Beran M; Estey E; Manshouri T; Kantarjian H; Keating MJ; Albitar M
Cancer; 2003 Jan; 97(2):441-9. PubMed ID: 12518368
[TBL] [Abstract][Full Text] [Related]
5. A Pilot Study of Aberrant CpG Island Hypermethylation of
Sun J; Zhang J; Wang Y; Li Y; Zhang R
Int J Med Sci; 2019; 16(2):324-330. PubMed ID: 30745814
[No Abstract] [Full Text] [Related]
6. Pathogenic Mutations Associated with Legius Syndrome Modify the Spred1 Surface and Are Involved in Direct Binding to the Ras Inactivator Neurofibromin.
Führer S; Tollinger M; Dunzendorfer-Matt T
J Mol Biol; 2019 Sep; 431(19):3889-3899. PubMed ID: 31401120
[TBL] [Abstract][Full Text] [Related]
7. Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia.
Huang X; Schwind S; Santhanam R; Eisfeld AK; Chiang CL; Lankenau M; Yu B; Hoellerbauer P; Jin Y; Tarighat SS; Khalife J; Walker A; Perrotti D; Bloomfield CD; Wang H; Lee RJ; Lee LJ; Marcucci G
Oncotarget; 2016 Sep; 7(37):59273-59286. PubMed ID: 27517749
[TBL] [Abstract][Full Text] [Related]
8. Legius syndrome, an Update. Molecular pathology of mutations in SPRED1.
Brems H; Legius E
Keio J Med; 2013; 62(4):107-12. PubMed ID: 24334617
[TBL] [Abstract][Full Text] [Related]
9. Analysis of mutations of neurofibromatosis type 1 gene and N-ras gene in acute myelogenous leukemia.
Lee YY; Kim WS; Bang YJ; Jung CW; Park S; Yoon WJ; Cho KS; Kim IS; Jung TJ; Choi IY
Stem Cells; 1995 Sep; 13(5):556-63. PubMed ID: 8528106
[TBL] [Abstract][Full Text] [Related]
10. Nucleophosmin Mutants Promote Adhesion, Migration and Invasion of Human Leukemia THP-1 Cells through MMPs Up-regulation via Ras/ERK MAPK Signaling.
Xian J; Shao H; Chen X; Zhang S; Quan J; Zou Q; Jin H; Zhang L
Int J Biol Sci; 2016; 12(2):144-55. PubMed ID: 26884713
[TBL] [Abstract][Full Text] [Related]
11. The GAP-related domain of neurofibromin attenuates proliferation and downregulates N- and K-Ras activation in Nf1-negative AML cells.
Morgan KJ; Rowley MA; Wiesner SM; Hasz DE; Van Ness B; Largaespada DA
Leuk Res; 2007 Aug; 31(8):1107-13. PubMed ID: 17222906
[TBL] [Abstract][Full Text] [Related]
12. RALB provides critical survival signals downstream of Ras in acute myeloid leukemia.
Eckfeldt CE; Pomeroy EJ; Lee RD; Hazen KS; Lee LA; Moriarity BS; Largaespada DA
Oncotarget; 2016 Oct; 7(40):65147-65156. PubMed ID: 27556501
[TBL] [Abstract][Full Text] [Related]
13. Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors.
Morgan MA; Wegner J; Aydilek E; Ganser A; Reuter CW
Leukemia; 2003 Aug; 17(8):1508-20. PubMed ID: 12886237
[TBL] [Abstract][Full Text] [Related]
14. NF1 inactivation revs up Ras in adult acute myelogenous leukemia.
Mullally A; Ebert BL
Clin Cancer Res; 2010 Aug; 16(16):4074-6. PubMed ID: 20587590
[TBL] [Abstract][Full Text] [Related]
15. Loss of the nf1 tumor suppressor gene decreases fas antigen expression in myeloid cells.
Hiatt K; Ingram DA; Huddleston H; Spandau DF; Kapur R; Clapp DW
Am J Pathol; 2004 Apr; 164(4):1471-9. PubMed ID: 15039234
[TBL] [Abstract][Full Text] [Related]
16. The neurofibromin recruitment factor Spred1 binds to the GAP related domain without affecting Ras inactivation.
Dunzendorfer-Matt T; Mercado EL; Maly K; McCormick F; Scheffzek K
Proc Natl Acad Sci U S A; 2016 Jul; 113(27):7497-502. PubMed ID: 27313208
[TBL] [Abstract][Full Text] [Related]
17. ras oncogene activation and occupational exposures in acute myeloid leukemia.
Taylor JA; Sandler DP; Bloomfield CD; Shore DL; Ball ED; Neubauer A; McIntyre OR; Liu E
J Natl Cancer Inst; 1992 Nov; 84(21):1626-32. PubMed ID: 1433344
[TBL] [Abstract][Full Text] [Related]
18. Mutational analysis of N-RAS and GAP-related domain of the neurofibromatosis type 1 gene in chronic myelogenous leukemia.
Garicochea B; Giorgi R; Odone VF; Dorlhiac-Llacer PE; Bendit I
Leuk Res; 1998 Nov; 22(11):1003-7. PubMed ID: 9783802
[TBL] [Abstract][Full Text] [Related]
19. Absence of rearrangement of the neurofibromatosis 1 (NF1) gene in myelodysplastic syndromes and acute myeloid leukemia.
Quesnel B; Preudhomme C; Vanrumbeke M; Vachee A; Lai JL; Fenaux P
Leukemia; 1994 May; 8(5):878-80. PubMed ID: 8182944
[TBL] [Abstract][Full Text] [Related]
20. Detection of N-RAS and K-RAS in their active GTP-bound form in acute myeloid leukemia without activating RAS mutations.
Ehmann F; Horn S; Garcia-Palma L; Wegner W; Fiedler W; Giehl K; Mayr GW; Jücker M
Leuk Lymphoma; 2006 Jul; 47(7):1387-91. PubMed ID: 16923573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
